Fulgent Genetics, Inc. (BMV:FLGT)
Mexico · Delayed Price · Currency is MXN | Market Cap | 8.57B -23.0% |
| Revenue (ttm) | 5.78B +9.5% |
| Net Income | -1.33B |
| EPS | -43.29 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 421 |
| Average Volume | 1,270 |
| Open | 492.50 |
| Previous Close | 450.00 |
| Day's Range | 492.50 - 492.50 |
| 52-Week Range | 315.00 - 492.50 |
| Beta | n/a |
| RSI | 55.49 |
| Earnings Date | May 1, 2026 |
About Fulgent Genetics
Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive he... [Read more]
Financial Performance
In 2025, Fulgent Genetics's revenue was $322.67 million, an increase of 13.83% compared to the previous year's $283.47 million. Losses were -$60.51 million, 41.7% more than in 2024.
Financial numbers in USD Financial StatementsNews
Fulgent Announces Rapid Oral Full Abstract Publication for FID-007 Within the Head and Neck Cancer Track Session at the ASCO 2026 Annual Meeting
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic...
Fulgent Genetics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
SAN DIEGO, May 20, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Fulgent Genetics, Inc. (NASDAQ: FLGT). The investigation focuses on Fulgent...
Lowey Dannenberg, P.C. is Investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for Potential Violations of the Federal Securities Laws and Encourages Investors to Contact the Firm
NEW YORK, May 08, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating Fulgent Genetics, Inc. (“Fulgent” or the “Com...
Fulgent Genetics price target lowered to $15 from $30 at Piper Sandler
Piper Sandler lowered the firm’s price target on Fulgent Genetics (FLGT) to $15 from $30 following quarterly results. The firm keeps a Neutral rating on the shares. Published first on…
Foundation Medicine to Launch FoundationOne®PGx, a Pharmacogenetic Offering, Through Expanded Partnership with Fulgent Genetics
BOSTON & EL MONTE, Calif.--(BUSINESS WIRE)--FoundationOne®PGx helps guide cancer therapy selection and dosing strategies to support safer, more effective patient care.
Fulgent Genetics Earnings Call Transcript: Q1 2026
Q1 2026 revenue declined due to a major customer transition, but acquisitions and new product launches are expected to drive growth. Guidance for 2026 is reaffirmed, with improved margins and reduced customer concentration risk anticipated.
Fulgent Genetics Earnings release: Q1 2026
Fulgent Genetics released its Q1 2026 earnings on May 1, 2026, summarizing the period's financial results.
Fulgent Genetics Slides: Q1 2026
Fulgent Genetics has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 1, 2026.
Fulgent Genetics Quarterly report: Q1 2026
Fulgent Genetics has published its Q1 2026 quarterly earnings report on May 1, 2026.
Fulgent Genetics reports Q1 EPS (36c) vs 4c last year
Reports Q1 revenue $71.1M vs $73.5M last year. Ming Hsieh, Chairman of the Board of Directors and Chief Executive Officer, said, “I am encouraged by our first quarter performance and…
Fulgent Reports First Quarter 2026 Financial Results
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeuti...
Fulgent Selected to Present Rapid Oral Abstract Within the Head and Neck Cancer Track Session at the 2026 ASCO Annual Meeting
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic...
Fulgent to Announce First Quarter 2026 Financial Results on Friday, May 1, 2026
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic...
Fulgent Genetics Proxy statement: Proxy filing
Fulgent Genetics filed a proxy statement on March 31, 2026, providing details for shareholder voting and corporate governance matters.
Fulgent Genetics Proxy statement: Proxy filing
Fulgent Genetics filed a proxy statement on March 31, 2026, providing details for shareholder voting and corporate governance matters.
Fulgent Genetics Completes Acquisition of Bako Diagnostics and StrataDx
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent”), a technology-based company with a well-established laboratory services business and a therapeutic development busi...
Fulgent Genetics, Inc. Investigated by the Portnoy Law Firm
LOS ANGELES, March 13, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Fulgent Genetics, Inc. (“Fulgent" or the "Company") (NASDAQ:FLGT) investors that the firm has initiated an investigation in...
Fulgent Genetics price target lowered to $22 from $35 at UBS
UBS lowered the firm’s price target on Fulgent Genetics (FLGT) to $22 from $35 and keeps a Buy rating on the shares.
Fulgent Genetics Earnings Call Transcript: Q4 2025
Revenue grew 14% in 2025 to $322.7M, with strong gains in precision diagnostics and anatomic pathology. 2026 guidance anticipates $350M revenue, offsetting a major customer loss with acquisitions and continued AI-driven efficiency.
Fulgent Genetics Annual report: Q4 2025
Fulgent Genetics has published its Q4 2025 annual report on February 27, 2026.
Fulgent Genetics Earnings release: Q4 2025
Fulgent Genetics released its Q4 2025 earnings on February 27, 2026, summarizing the period's financial results.
Fulgent Genetics Slides: Q4 2025
Fulgent Genetics has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 27, 2026.
Fulgent Genetics reports Q4 EPS 16c, consensus 3c
Reports Q4 revenue $83.34M, consensus $85.38M. Ming Hsieh, chairman and CEO, said, “I am pleased with the progress we made in 2025 as we delivered on our strategic and product…
Fulgent Genetics sees FY26 EPS ($1.45), consensus (32c)
Sees FY26 revenue $350M, consensus $356.29M. Sees FY26 cash, cash equivalents, restricted cash, and investments in marketable securities of approximately $685M. Paul Kim, CFO, said, “In 2025, we demon...